Filing Flows › Comparisons › ISCO vs TVRD
International Stem Cell vs Tvardi Therapeutics: ISCO and TVRD compared
International Stem Cell is the larger company: $2.7M of revenue in its latest quarter (Q2 2026) against $2.6M for Tvardi Therapeutics (Q1 2025). Tvardi Therapeutics is growing faster (+20% against +9% a year earlier). International Stem Cell is more profitable, with an operating margin of -1.3% against -92.9%.
Where the money goes: ISCO and TVRD
International Stem Cell (ISCO) · Q2 2026
International Stem Cell, Q2 2026: revenue $2.7M (+9% year over year), operating margin -1.3%, net loss $71K, operating cash flow $167K. The chart follows the revenue to costs, profit and cash.
Tvardi Therapeutics (TVRD) · Q1 2025
Tvardi Therapeutics, Q1 2025: revenue $2.6M (+20% year over year), operating margin -92.9%, net loss $4.9M, operating cash flow −$4.7M. The chart follows the revenue to costs, profit and cash.
| International Stem Cell (ISCO) | Tvardi Therapeutics (TVRD) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q1 2025 |
| Revenue | $2.7M | $2.6M |
| Revenue growth, Y/Y | +9% | +20% |
| Operating margin | -1.3% | -92.9% |
| Net earnings | −$71K | −$4.9M |
| Net margin | -2.7% | -191.0% |
| Operating cash flow | $167K | −$4.7M |
| Free cash flow | $160K | — |
Where the revenue comes from
International Stem Cell
- Biomedical Market: $2.5M (94%)
- Anti Aging Skincare Market: $151K (6%)
Tvardi Therapeutics
- Other revenue: $1.3M (51%)
- Collaborative revenue: $1.2M (47%)
- Clinical compound revenue: $48K (2%)
Questions
Which is bigger, International Stem Cell or Tvardi Therapeutics?
International Stem Cell is the larger company: $2.7M of revenue in its latest quarter (Q2 2026) against $2.6M for Tvardi Therapeutics (Q1 2025).
Is International Stem Cell or Tvardi Therapeutics growing faster?
Tvardi Therapeutics is growing faster (+20% against +9% a year earlier).
Which is more profitable, International Stem Cell or Tvardi Therapeutics?
International Stem Cell is more profitable, with an operating margin of -1.3% against -92.9%.
More: International Stem Cell earnings · how International Stem Cell makes money · Tvardi Therapeutics earnings · how Tvardi Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 13, 2026; 10-Q filed May 13, 2025). Fiscal quarters can end on different dates. Not investment advice.